Email updates

Keep up to date with the latest news and content from BMC Medicine and BioMed Central.

Journal App

google play app store
Open Access Commentary

Location, location, location: the BRMS1 protein and melanoma progression

Adam I Riker1* and Rajeev S Samant2

Author Affiliations

1 Advocate Christ Medical Center, Advocate Cancer Institute, Oak Lawn, IL, USA

2 Department Oncologic Sciences, Mitchell Cancer Institute, University South Alabama, Mobile, AL, USA

For all author emails, please log on.

BMC Medicine 2012, 10:19  doi:10.1186/1741-7015-10-19

Published: 22 February 2012


The metastasis suppressor, BRMS1, has been demonstrated to cause dramatic regression of metastatic lesions without blocking orthotopic tumor growth. The role of BRMS1 is well-documented for several non-melanoma malignancies, such as breast cancer, ovarian cancer and non-small-cell lung cancer. However, its role in melanoma is just beginning to be understood, with a recent article by Slipicevic et al. highlighting the levels of expression of BRMS1 in benign nevi, primary and metastatic melanoma samples. Their findings emphasize that the intracellular location of BRMS1 protein (cytoplasmic or nuclear), appears to have a significant impact upon the metastatic capacity of melanoma cells. Interestingly, this selective localization translates into a statistically significant decrease in the relapse-free period in melanoma patients, further associated with a thicker Breslow's depth of primary melanomas. However, and more importantly, this study begins to define a clearer role for BRMS1 in melanoma that is strictly dependent upon its cellular location, with nuclear expression associated with invasive and metastatic capacity and cytoplasmic expression resulting in repressive effects upon progression and metastasis.

Please see related article: webcite

BRMS1; melanoma; metastasis; tumor suppressor